Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH).

Trial Profile

Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder; Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms AGOPSYCH
  • Most Recent Events

    • 01 Dec 2016 Results assessing safety and efficacy published in the Journal of Clinical Psychopharmacology.
    • 19 Nov 2016 Status changed from recruiting to completed, accoring to results published in the Journal of Clinical Psychopharmacology.
    • 01 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01822418).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top